Skip to main content
. 2021 May 27;9(6):E943–E954. doi: 10.1055/a-1464-0809

Table 3. Patient characteristics after propensity score weighting.

Characteristics Expert, % Nonexpert, % P value Standarized difference
Age, mean ± SD 67.5 ± 10.0 67.6 ± 10.1 0.966 0.011969
Sex, male (%) 67.6 67.3 0.971 0.04153
Body mass index, mean ± SD 23.4 ± 2.3 23.5 ± 2.2 0.807 0.044433
Comorbidities

  • Previous lower GI bleeding (%)

 32.0 33.2 0.896 0.20694

  • Charlson comorbidity index

 0.7 ± 0.7 0.7 ± 0.9 0.9 0

  • Ischemic heart diseases (%)

 6.8 7.1 0.943 0.11416

  • Chronic obstructive pulmonary disease (%)

 51 51 0.999 0

  • Peptic ulcer (%)

 3.6 4.4 0.825 0.41008

  • Liver cirrhosis (%)

 0 0 0.812 0

  • Diabetes mellitus (%)

 12.4 12.0 0.954 0.10899

  • Chronic heart failure (%)

 0 0 0.549 Not applicable

  • Cerebral vascular diseases (%)

 12.3 11.9 0.943 0.12952

  • Dementia (%)

 0 0 Not applicable

  • Collagen diseases (%)

 5.0 4.7 0.935 0.1495

  • Chronic kidney disease (%)

 6.3 7.6 0.778 0.49294

  • Leukemia (%)

 0 0 Not applicable

  • Malignant lymphoma (%)

 0 0 Not applicable

  • Solid cancer (%)

 8.1 8.0 0.993 0.01764

  • Metastatic cancer (%)

 0 0 Not applicable

  • Acquired immunodeficiency syndrome

 0 0 Not applicable
Medication

  • Low dose aspirin

 14.0 14.1 0.983 0.03736

  • Thienopyridine

 5.2 4.7 0.906 0.22894

  • Cilostazol

 3.6 3.0 0.851 0.36283

  • Other antiplatelet drugs

 3.4 3.1 0.94 0.1275

  • Warfarin

 2.5 2.4 0.969 0.06442

  • Direct oral anticoagulants

 4.4 3.8 0.875 0.28242

  • NSAIDs

 17.2 18.5 0.858 0.31727
Initial assessment

  • Hemodynamic instability

 5.6 4.4 0.783 0.54683

  • Hemoglobin, g/dL

 11.9 ± 1.5 11.8 ± 1.9 0.909 0.058421

  • Upper endoscopy before colonoscopy

 0 0 0.712 0

  • Early colonoscopy group

 41.9 44.7 0.776 0.41894

Parenthesis shows %.

NSAIDs, nonsteroidal anti-inflammatory drugs.